Melvalonates, Ras and Breast Cancer
Abstract
Therapy of any cancer is designed to control the growth of cancer cells while permitting the function and proliferation of normal cells. 6-fluoromevalonate (Fmev) can inhibit proliferation of leukemic cell lines while not affecting normal lymphocytes. Here, we are evaluating the ability of Fmev to selectively interfere with proliferation of breast cancer cells. We have shown that Fmev can inhibit proliferation of normal breast epithelial cells. However, the proliferation of epithelial cells expressing oncogenic Ras is inhibited by concentrations of Fmev that do not appreciably affect the proliferation of normal breast epithelial cells. These results suggest that Fmev has potential efficacy as a breast cancer therapeutic. These observations are being extended with the use of breast tumor derived cells lines, and by an examination of the molecular mechanism of growth inhibition.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2000
- Accession Number
- ADA388129
Entities
People
- Michael A. White
Organizations
- University of Texas Southwestern Medical Center